Abstract
Previous studies have shown that the regular administration of short acting β -agonists can be associated with adverse effects on airway caliber and bronchial hyperresponsiveness (BHR) and that this may occur through a proinflammatory mechanism. The aim was to explore possible adverse effects of high-dose β -agonist therapy and to assess any adverse interaction with corticosteroids. We undertook a randomized, crossover study to investigate the effects of 6 wk of treatment with regular terbutaline (1 mg four times a day), regular budesonide (400 μ g twice a day), combined treatment, and placebo in subjects with mild to moderate asthma. Major endpoints were PD15 saline, PD20 methacholine, and induced sputum differential cell counts. Thirty-four subjects were randomized and 28 completed the study. PD15 saline decreased on terbutaline alone compared with placebo treatment and on combined treatment compared with budesonide alone (mean fold decrease of 0.57 [95% CI = 0.36, 0.90] and 0.65 [95% CI = 0.43, 0.97], respectively). PD20 methacholine was not affected by the use of terbutaline either alone or in combination with budesonide. The percentage of eosinophils in induced sputum increased during terbutaline treatment alone compared with placebo (median 8.3% versus 4.4%, p = 0.049). The addition of terbutaline to budesonide did not affect the percentage of eosinophils compared with budesonide treatment alone. These findings support the hypothesis that short-acting β -agonists have a permissive effect on airway inflammation and that when used in high dose there may be an unfavorable interaction with inhaled corticosteroids.
Inhaled corticosteroids and short-acting β-agonists are very widely used in the treatment of patients with asthma. The beneficial effects of corticosteroids, which include improvement in airway caliber, bronchial hyperresponsiveness (BHR), and airway inflammation, are well documented (1). Although short- acting β-agonists are undoubtedly safe when used as required for the relief of acute symptoms, their regular use has been shown to have adverse effects (2). Continuous use of short-acting β-agonist has been associated with deleterious effects on peak expiratory flow rates (PEFR), spirometric values, and BHR to methacholine, histamine, and allergen (3, 4). The clinical significance of these effects has been widely debated (3, 5).
The adverse changes in BHR have been more readily demonstrated when bronchoconstriction involves indirect cellular mechanisms (adenosine monophosphate [AMP], allergen) rather than stimulation of smooth muscle directly (histamine, methacholine) (6-10). These findings have generated the hypothesis that the regular administration of short-acting β-agonist may have a permissive effect on underlying airway inflammation (4).
The effects of regular short-acting β-agonist on airway inflammation have only been investigated in three studies to our knowledge. In one study, an increase in the total number of eosinophils and their activation status in bronchial biopsies was demonstrated (11). In another, no change in bronchoalveolar lavage cell count or eosinophil cationic protein level (12) was observed. In contrast, in a third study short-acting β-agonist treatment resulted in a reduction in lymphocyte number with no change in eosinophil numbers in bronchial biopsies (13).
The combination of short-acting β-agonist with inhaled corticosteroid has not been extensively investigated; however, there is some evidence to suggest that β-agonists may impair the anti-inflammatory effects of corticosteroids (8, 14, 15). Clinical interactions between short-acting β-agonists and corticosteroids have recently been studied by our group (16). We found that morning PEFR, FEV1, and BHR to methacholine were improved with corticosteroid, and that the addition of regular terbutaline improved clinical indices.
This new study was designed to extend our observations on the effect of combining short-acting β-agonists with corticosteroids, particularly in light of the proposed negative interaction between these two drugs at a molecular level (14). We wished to examine the effects of short-acting β-agonists and corticosteroids on inflammatory indices in induced sputum, and to compare the effect of treatment on BHR to hypertonic saline and methacholine. We hypothesized that regular short-acting β-agonist treatment would be associated with increased airway inflammation and that any such adverse effects would be more readily detected by assessing BHR to hypertonic saline (indirect cellular mechanism) than to methacholine (direct smooth muscle mechanism).
Subjects age 16 to 64 yr with mild to moderate asthma for more than 1 yr were recruited. All subjects were atopic (positive skin test to Dermatophagoides pteronyssinus, mixed grass pollen, or cat pelt), and demonstrated BHR to methacholine (provocative dose causing a 20% fall in FEV1 [PD20] or provocative concentration causing a 20% fall in FEV1 [PC20] < 8 μmol or < 12 μmol if taking inhaled corticosteroid), but had an FEV1 > 50% predicted. They also needed to be able to produce sputum after induction with 4.5% hypertonic saline. Subjects were excluded if they had any other serious concurrent medical illness, if they had a smoking history of more than 5 pack-years, or if they had smoked tobacco in the preceding year. Subjects taking more than 1,500 μg of inhaled corticosteroid per day, or who had required oral corticosteroids during the previous 3 mo, were also excluded. All subjects gave written informed consent and the study was approved by the Canterbury and Otago Ethics Committees.
This was a randomized, double-blind, placebo-controlled, double-dummy, crossover study. During a prerandomization run-in period, all asthma medications were withdrawn except short-acting bronchodilators, together with any intranasal corticosteroid treatment. For the following 4 wk subjects recorded their peak flow rates and symptoms twice daily in a diary. Provided they did not become clinically unstable, subjects were then randomized to receive the following treatments, each for 6 wk: (1) terbutaline Turbuhaler 500 μg 2 puffs four times a day and placebo Turbuhaler 1 puff twice a day; (2) placebo Turbuhaler 2 puffs four times a day and budesonide Turbuhaler 400 μg 1 puff twice a day; (3) terbutaline Turbuhaler 500 μg 2 puffs four times a day and budesonide Turbuhaler 400 μg 1 puff twice a day; (4) placebo Turbuhaler 2 puffs four times a day and placebo Turbuhaler 1 puff twice a day.
The trial medication and matching placebos were supplied by Astra Draco, Lund, Sweden. During the treatment periods, subjects were instructed to use ipratropium bromide 40 μg via metered-dose inhaler (Boehringer Ingelheim, Germany) for relief of symptoms but no other asthma medication was permitted except in the event of a severe asthma attack. At the end of each 6-wk period, subjects underwent a combined hypertonic saline challenge/sputum induction procedure. Three to 7 d later, they underwent a methacholine challenge test. At this visit, study medication for the next period was issued to the subjects. Whenever possible, the challenge tests were performed at the same time of day. Study medication and ipratropium were withheld either overnight (for subjects whose challenge tests were conducted in the morning), or for at least 6 h before each challenge test performed late in the day.
Subjects were monitored closely throughout the study and had 24-h access to a medical investigator together with an emergency supply of prednisone tablets and a salbutamol inhaler. In the event of a subject experiencing an exacerbation sufficiently severe to warrant additional treatment, they were temporarily withdrawn from the study. Thereafter, if considered clinically appropriate, subjects were reentered into the next treatment period once their asthma had restabilized. Subjects had to have discontinued oral and inhaled corticosteroids for at least 4 wk before they could rejoin the study. Treatment periods interrupted by asthma exacerbations were not repeated.
Airway caliber. PEFR were measured twice daily using a mini-Wright peak flow meter (Clement Clarke Int. Ltd, Harlow, UK) as the highest of three values taken prior to morning and evening study medication. FEV1 was measured using a rolling seal spirometer (Spirotech; Graseby, Smyrna, GA) and was taken as the highest of three reproducible maneuvers recorded at the end of each treatment period immediately before the saline challenge.
Symptom diary. The following daytime symptoms were documented daily in a diary on a score of 0 to 3: wheeze, breathlessness on activity, cough, and sputum production. Similarly nighttime symptoms of nocturnal wakening, wheeze, and cough were recorded. The use of ipratropium was recorded twice daily.
Hypertonic saline challenge/sputum induction procedure. Baseline FEV1 was recorded. Nebulized 4.5% saline was generated from an ultrasonic nebulizer (Ultra-Neb 2000; DeVilbiss, Somerset, PA) using large bore tubing, a large two-way nonrebreathing valve (2700; Hans Rudolph Inc., Kansas City, MO) and rubber mouthpiece (mean nebulizer output to subjects = 1.6 ml/min). The saline was inhaled for the following time periods: 0.5, 0.5, 1, 2, 4, 4, 4, 4 min (modified version of Iredale and coworkers [17]). FEV1 was measured 1 min after each period of inhalation. Between each inhalation period, subjects rinsed their mouth with water and were encouraged to cough sputum into a plastic container. The challenge procedure was stopped if the FEV1 fell more than 20% from baseline, and subjects were given salbutamol 200 μg from a metered-dose inhaler via spacer. Spirometry was repeated after 5 min. At this point the inhalation regimen was restarted in order to collect more sputum, provided the subject's FEV1 was greater than 90% of baseline value. The procedure was stopped after 20 min or after an adequate sputum sample had been obtained. The nebulizer output was calculated by weighing the nebulizer canister before and immediately after the challenge test. The cumulative dose of saline causing a 15% decrease in FEV1 (PD15 saline) was calculated by linear interpolation on the log dose response plot.
Methacholine challenge test. BHR to methacholine was measured using a modified version of the rapid challenge procedure (18). After measurement of the baseline FEV1, subjects inhaled nebulized 0.9% saline as a control, followed by a series of doubling doses of methacholine (0.044 to 44 μmol taken in one or two breaths), from a Nebicheck dosimeter (P.K. Morgan Ltd, Gillingham, Kent, UK). FEV1 was measured 1 min after each dose, and immediately after this the subjects inhaled the next dose of methacholine. The test was stopped when the FEV1 had fallen by greater than 20% from the postsaline value or when the highest dose had been administered. The cumulative provocation dose of methacholine causing a 20% reduction in FEV1 (PD20 methacholine) was calculated by linear interpolation between the last two readings on the log dose response plot.
Sputum processing and analysis. The entire expectorated sample was homogenized by the addition of 1% dithiothreitol (the volume of 1% dithiothreitol added equating to 3 times the weight of the sputum sample) (Sputolysin; Calbiochem, La Jolla, CA) (19). The mixture was then placed in a rocking waterbath at 37° C for 30 min to ensure complete dispersion before being filtered through a 48-μm nylon mesh (B&SH Thompson, Mississauga, ON, Canada). The total cell count, percentage squamous cells, and percentage cell viability (trypan blue exclusion) were determined using a hemocytometer. An aliquot was diluted to obtain a concentration of approximately 1 × 105 cells/ml from which cytospins were prepared (Shandon 2; Shandon Southern Products Ltd, Runcorn, Cheshire, UK). The remaining sputum mixture was centrifuged at 1,350 × g for 5 min, the supernatant decanted and frozen at −80° C for future analysis.
Sputum cell counts. Cytospins were stained with May Grunwald Giemsa and a 400 differential cell count (excluding squamous cells) was determined in duplicate.
Results were analyzed for all subjects who completed two or more treatment periods (n = 28). Diary data from the first 2 wk of each treatment period were excluded to minimize the influence of any carry-over effect and to remove the need for a washout period. Each symptom was analyzed as the percentage of symptomatic days or nights reported during the treatment period. Similarly, the use of ipratropium was analyzed as the percentage of days and nights during which it was taken.
Normally distributed data (FEV1, PEFR, log PD15 saline, and log PD20 methacholine) were initially assessed for an overall treatment effect using a general linear model repeated-measures analysis. If a significant treatment effect was revealed, further analysis of each of the six pairwise comparisons using the paired t test was undertaken. Nonparametric data (percentage of days with each symptom and in which ipratropium was used and the percentages of each cell type in sputum) were initially assessed with Friedman's test, and if appropriate, analyzed in pairs using the Wilcoxon signed-rank test. A p value of < 0.05 was considered statistically significant. Parametric data are plotted as the mean with the least significant difference, nonparametric data as the median with the interquartile range. All statistical tests were performed using SPSS version 8.0 software (SPSS Inc., Chicago, IL).
Fifty-two subjects were initially recruited to the study. Eighteen of these were withdrawn before randomization because of deteriorating asthma (11), the inability to produce sputum (4), social reasons (2), or because a PD20 methacholine was not achieved (1). The clinical characteristics of the 34 randomized subjects are shown in Table 1. Of these, 28 (82%) completed the study, with four subjects withdrawn on account of poor asthma control and two for social reasons. As these subjects all withdrew during the first or second treatment periods, treatment comparisons were only performed on the 28 remaining subjects. During the study proper, six exacerbations occurred in five of the 28 subjects. Three of these occurred in the terbutaline alone treatment period, and three in the placebo period. One subject withdrew in the placebo period after completing the saline challenge test but before the methacholine challenge was performed.
| Age, mean, yr | 39 (range 18–61) | |
| Sex, male:female | 18:16 | |
| Inhaled corticosteroids* at entry | ||
| None | 12 (35.0%) | |
| 1–250 μg/d | 8 (23.5%) | |
| 251–500 μg/d | 8 (23.5%) | |
| 501–1,000 μg/d | 6 (18.0%) | |
| FEV1, mean, L | 3.05 (95% CI = 2.76–3.35) | |
| FEV1, % predicted, mean | 89.5 (95% CI = 85.2–93.9) |
Analysis of the PEFR data on a week-by-week basis revealed no time trends. Morning PEFR (Table 2 and Figure 1) was significantly higher on budesonide than on terbutaline or placebo treatment (+19 L/min, p = 0.043 and +17 L/min, p = 0.001, respectively). Morning PEFR was further increased on combined treatment compared with budesonide alone (+22 L/min, p = 0.001). There was no significant difference in morning PEFR between terbutaline and placebo. Evening PEFR (Table 2) was significantly higher on budesonide compared with placebo treatment (+15 L/min, p = 0.005), and significantly higher on terbutaline versus placebo treatment (+30 L/min, p < 0.001). There was no significant difference in evening PEFR between budesonide and terbutaline. Combined treatment resulted in a higher evening PEFR than any of the other treatments (p < 0.001).
| Treatment | Treatment Effects (p Value) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P | T | B | C | P versus T | P versus B | P versus C | T versus B | T versus C | B versus C | |||||||||||
| Morning PEFR, L/min | 452 | 450 | 469 | 491 | 0.484 | 0.001 | < 0.001 | 0.043 | < 0.001 | 0.001 | ||||||||||
| 412–491 | 411–490 | 429–509 | 451–531 | |||||||||||||||||
| Evening PEFR, L/min | 452 | 482 | 467 | 502 | < 0.001 | 0.005 | < 0.001 | 0.168 | 0.001 | < 0.001 | ||||||||||
| 412–492 | 443–521 | 427–507 | 460–543 | |||||||||||||||||
| Daytime wheeze, % days present | 25 | 18 | 9 | 4 | 0.287 | 0.064 | 0.001 | 0.267 | 0.020 | 0.126 | ||||||||||
| 4–74 | 3–51 | 0–32 | 0–18 | |||||||||||||||||
| Nighttime wheeze, % nights present | 16 | 12 | 4 | 3 | 0.879 | 0.033 | 0.001 | 0.099 | 0.003 | 0.131 | ||||||||||
| 1–48 | 0–63 | 0–36 | 0–12 | |||||||||||||||||
| Daytime ipratropium use, % days used | 6 | 0 | 0 | 0 | 0.006 | 0.039 | 0.002 | 0.777 | 0.184 | 0.049 | ||||||||||
| 0–40 | 0–13 | 0–25 | 0–6 | |||||||||||||||||
| FEV1, L | 2.95 | 2.90 | 3.21 | 3.07 | 0.824 | 0.002 | 0.042 | < 0.001 | 0.019 | 0.030 | ||||||||||
| 2.60–3.29 | 2.58–3.21 | 2.88–3.53 | 2.77–3.37 | |||||||||||||||||
| PD15, saline, ml | 5.34 | 3.18 | 11.44 | 8.00 | 0.019 | 0.001 | 0.102 | < 0.001 | < 0.001 | 0.039 | ||||||||||
| 3.39–8.42 | 2.06–4.92 | 8.17–16.0 | 5.36–11.9 | |||||||||||||||||
| PD20 methacholine, μmol | 0.72 | 0.52 | 2.81 | 2.29 | 0.228 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.254 | ||||||||||
| 0.46–1.13 | 0.30–0.92 | 1.59–5.11 | 1.24–4.26 | |||||||||||||||||
| Sputum % eosinophils | 4.4 | 8.3 | 1.7 | 2.1 | 0.049 | 0.021 | 0.056 | < 0.001 | < 0.001 | 0.409 | ||||||||||
| 1.7–9.8 | 3.1–14.7 | 1.0–3.6 | 0.7–3.9 | |||||||||||||||||
| Sputum % neutrophils | 28.5 | 23.0 | 23.4 | 27.9 | No significant treatment effect | |||||||||||||||
| 20.0–36.7 | 15.8–44.4 | 13.6–42.1 | 13.5–46.5 | |||||||||||||||||
| Sputum % lymphocytes | 0.5 | 0.5 | 0.5 | 0.2 | No significant treatment effect | |||||||||||||||
| 0.4–1.2 | 0.5–0.9 | 0.2–0.9 | 0.0–0.7 | |||||||||||||||||
| Sputum % macrophages | 57.0 | 46.8 | 63.8 | 53.0 | No significant treatment effect | |||||||||||||||
| 42.5–69.0 | 26.7–69.3 | 40.8–75.7 | 40.6–68.4 | |||||||||||||||||
| Sputum % epithelial cells | 4.6 | 4.4 | 6.1 | 5.6 | No significant treatment effect | |||||||||||||||
| 2.2–8.1 | 2.4–12.9 | 1.5–13.6 | 3.0–16.8 | |||||||||||||||||
Fig. 1. Treatment effects for morning PEFR. Data are displayed as mean (square symbol ) with error bars representing the least significant difference at the 5% level.
[More] [Minimize]Analysis of the diary data on a week-by-week basis revealed no time trends. No significant treatment effects were seen for nighttime wakening, cough, sputum production, or breathlessness on activity. The percentage of days and nights with wheeze decreased on budesonide treatment, when given alone or in combination with terbutaline (Table 2). The addition of terbutaline to placebo or budesonide did not result in any significant changes. The percentage of days on which ipratropium was used fell for all three treatments compared with placebo (p < 0.04).
FEV1 data are shown in Table 2 and Figure 2. FEV1 was higher on budesonide treatment compared with terbutaline or placebo treatment (+0.31 L, p < 0.001, and +0.26 L, p = 0.002, respectively). Similarly, FEV1 was higher on the combined treatment compared with terbutaline or placebo treatment alone (+0.17 L, p = 0.019, and +0.12 L, p = 0.042, respectively). FEV1 was lower on combined treatment compared with budesonide alone (−0.14 L, p = 0.030). There was a trend toward a lower FEV1 on terbutaline compared with placebo but this did not reach statistical significance.
Fig. 2. Treatment effects for FEV1. Data are displayed as mean (square symbol ) with error bars representing the least significant difference at the 5% level.
[More] [Minimize]A PD15 saline was achieved in 88 (82%) of the 107 saline challenge tests conducted during the randomized periods. Linear extrapolation, equivalent to a further 4 min of saline administration, allowed an additional two cases to be included in the analysis. For the remaining challenges an arbitrary value of 30 ml (> maximal calculated PD15 value) was assigned. PD15 saline data are shown in Table 2 and Figure 3. PD15 saline was higher on budesonide treatment compared with terbutaline or placebo treatment: 3.99-fold increase (95% confidence interval [CI] = 2.32, 6.88) and 2.32 (95% CI = 1.48, 3.63), respectively. PD15 saline was lower on terbutaline compared with placebo treatment and on combined treatment versus budesonide alone (0.57-fold decrease [95% CI = 0.36, 0.90] and 0.65 [95% CI = 0.43, 0.97], respectively). There was no significant difference in PD15 saline on combined treatment compared with placebo. There was no relationship between changes in FEV1 and changes in BHR to saline in any of the treatment groups (data not shown).
Fig. 3. Treatment effects for PD15 saline. Data are displayed as geometric mean (square symbol ) with error bars representing the least significant difference at the 5% level.
[More] [Minimize]A PD20 methacholine was achieved in 103 (97%) of the 106 methacholine challenge tests conducted during the randomized periods. For the three remaining challenge tests an arbitrary value of 54 μmol (> maximal calculated PD20 value) was assigned. PD20 methacholine data are shown in Table 2 and Figure 4. PD20 methacholine was higher on budesonide treatment compared with terbutaline or placebo treatment (5.08-fold increase [95% CI = 2.73, 9.48] and 3.86 [95% CI = 2.39, 6.22], respectively). Similarly PD20 methacholine was higher on the combined treatment compared with terbutaline or placebo treatment (4.23-fold increase [95% CI = 2.49, 7.19] and 3.31 [95% CI = 2.17, 5.05], respectively). There was no significant difference in PD20 methacholine on combined treatment versus budesonide alone, or for terbutaline compared with placebo.
Fig. 4. Treatment effects for PD20 methacholine. Data are displayed as geometric mean (square symbol ) with error bars representing the least significant difference at the 5% level.
[More] [Minimize]Sputum quality (total cell count, percent squamous cell, percent cell viability) did not significantly differ between treatment periods (Table 3). There was a significant treatment effect for the percentage of eosinophils in sputum (Table 2, Figure 5) but not for any of the other cell types. Eosinophils were lower on budesonide treatment compared with terbutaline or placebo treatment (−6.6%, p < 0.001 and −2.7%, p = 0.012, respectively). The percentage of eosinophils was higher on terbutaline compared with placebo treatment (+3.9%, p = 0.049). There was no significant difference for eosinophils on combined treatment compared with budesonide alone.
| Treatment | ||||||||
|---|---|---|---|---|---|---|---|---|
| P | T | B | C | |||||
| Total cell count, × 109/L | 1.27 | 1.97 | 1.50 | 1.96 | ||||
| (0.87–2.83) | (0.99–2.89) | (1.14–2.70) | (1.38–2.90) | |||||
| Squamous cells, % | 5.3 | 5.3 | 5.6 | 4.0 | ||||
| (3.1–11.4) | (2.9–8.9) | (3.4–10.6) | (1.6–8.5) | |||||
| Cell viability, % | 80 | 77 | 74 | 77 | ||||
| (74–84) | (72–85) | (67–84) | (74–84) | |||||
Fig. 5. Treatment effect on % sputum eosinophils. Data are displayed as median with interquartile range, 10th and 90th percentiles, and outliers. * P = significantly different from placebo, * T = significantly different from terbutaline, * B = significantly different from budesonide, * C = significantly different from combined treatment, p < 0.05.
[More] [Minimize]The results of this investigation provide additional data concerning the proinflammatory as well as the anti-inflammatory effects of the two drug therapies most commonly used in the management of chronic asthma, namely inhaled β-agonists and corticosteroids. Although it is no longer recommended that short-acting β-agonists be taken regularly, many patients use short-acting agents frequently in addition to their anti-inflammatory medication. For this reason investigating possible interactions between the two drugs is clinically relevant, and the design of our study reflected this objective.
The principal finding was that high-dose terbutaline alone resulted in a significant increase in sputum eosinophils and BHR to saline when compared with placebo. There were no significant changes in symptoms, BHR to methacholine, morning PEFR, or FEV1. These data indicate that when given as monotherapy in our patients, β-agonist alone had a proinflammatory effect although no major impact on lung function was observed.
The effects of regular short-acting β-agonists on measurements of lung function and BHR to methacholine, histamine, and allergen have been reviewed previously (3), although not all published studies have reported negative effects consistently. The adverse effects of β-agonist on more specific measures of airway inflammation have not been studied as extensively. The increase in sputum eosinophils seen in the present study is in keeping with the results of a previous investigation in which an increase in both the total number of eosinophils and their activation status was observed with regular short-acting β-agonist (11). Similarly, short-acting β-agonist has been shown to augment the increase in sputum eosinophils and eosinophilic cationic protein observed after allergen challenge (20). Moreover, the administration of regular short-acting β-agonist to subjects with an early asthmatic response to allergen has been shown to increase the likelihood of developing a dual asthmatic response, suggesting a proinflammatory action (21). In vitro, exposure of blood eosinophils to short-acting β-agonist resulted in a dose-dependent increase in their respiratory burst, suggesting that short-acting β-agonists may affect eosinophil activation status directly (22).
Terbutaline treatment resulted in increased BHR to saline but not to methacholine. A similar difference between saline and methacholine has been observed previously in a study which examined the effects of regular inhaled salbutamol in nonasthmatic atopic subjects (23). Short-acting β-agonists have been shown to have a greater effect on BHR when the mechanism of induced bronchoconstriction involves indirect pathways such as allergen rather than direct stimulation of bronchial smooth muscle (6-10). Moreover, the loss of the acute protective effect of short-acting β-agonists during regular treatment is more obvious using indirect provocation stimuli such as AMP, than with directly acting nonspecific stimuli such as methacholine (6). Hypertonic saline is thought to cause bronchoconstriction via indirect cellular mechanisms, notably stimulation of mast cells and local sensory nerves (24). Our data suggest that saline challenge may be a more sensitive measurement of airway inflammation.
Our study was also designed to test the hypothesis that the benefits of inhaled corticosteroid might be compromised when inhaled β-agonist was given in combination. When given as monotherapy, budesonide treatment resulted in a reduction in sputum eosinophils, a reduction in BHR to hypertonic saline and methacholine, and improved lung function. These effects are well-documented in the literature (25-28). The combination of budesonide with terbutaline, however, provided contrasting outcomes. On the one hand, there was no significant difference in sputum eosinophils with combined treatment compared with budesonide alone. On the other, combined treatment appeared to negate the improvement in BHR to saline—but not to methacholine—obtained with budesonide: PD15 saline on combined treatment was not significantly different from placebo. This pattern of differential effects on BHR has been noted previously. In a crossover study in 13 asthmatics, Cockcroft and coworkers demonstrated that compared with treatment with budesonide alone, BHR to allergen but not methacholine was increased when salbutamol was simultaneously administered (8). Similarly, in a parallel group study of 41 patients, Wong and colleagues found that the protective effect of 2 to 4 wk treatment with budesonide against allergen challenge was reduced in patients receiving regular terbutaline (15). In our study, we also observed that FEV1 was significantly lower on combined treatment than with budesonide alone. This pattern is different from that for mean morning PEFR, an observation which has been made previously (15, 29). The explanation for these differential effects on measurements of lung function is unclear.
The clinical relevance of our findings remains uncertain. Our earlier crossover study did not reveal any adverse changes in asthma control with terbutaline treatment, either as monotherapy or in combination with budesonide (16). In fact, the combination of terbutaline and budesonide was ranked best of the four treatments using a hierarchy of relevant clinical endpoints. In this study, despite the proinflammatory effects of terbutaline, no clinically important negative effect has been identified. However, patients recruited into these two studies were necessarily required to tolerate the withdrawal of inhaled corticosteroid during the run-in period, and thus only patients with mild asthma were enrolled. It is possible that the proinflammatory actions of short-acting β-agonists may counterbalance the benefits of inhaled corticosteroid treatment when subjects with more severe asthma are studied, or when different dose combinations of the two drugs are used, or when subjects are investigated over longer periods of time. This might explain the adverse effect on asthma control which has been observed in some studies despite the use of anti-inflammatory treatment (30, 31). Certainly, our observations reinforce current guidelines that short-acting agents should be used only “as required,” and ought to prompt clinicians to carefully review patients whose asthma is poorly controlled and whose use of β-agonist as “reliever” is excessive.
The authors thank the volunteers for participating in this study, Timothy Chan for performing the analyzis of induced sputum, and Erin Flannery and Christine McLachlan for helping with the challenge testing.
| 1. | Barnes P. J.Efficacy of inhaled corticosteroids in asthma. J. Allergy Clin. Immunol.1021998531538 |
| 2. | Sears M. R., Taylor D. R.The beta 2-agonist controversy: observations, explanations and relationship to asthma epidemiology. Drug Safety111994259283 |
| 3. | Taylor D. R., Sears M. R., Cockcroft D. W.The β-agonist controversy. Med. Clin. North Am.801996719748 |
| 4. | Cockcroft D. W., Swystun V. A.Functional antagonism: tolerance produced by inhaled beta-2 agonists. Thorax51199610511056 |
| 5. | Barrett T. E., Strom B. L.Inhaled beta-adrenergic receptor agonists in asthma: more harm than good? Am. J. Respir. Crit. Care Med.1511995574577 |
| 6. | O'Connor B. J., Aikman S. L., Barnes P. J.Tolerance to the non-bronchodilator effects of inhaled beta 2-agonists in asthma. N. Engl. J. Med.327199212041208 |
| 7. | Taylor D. A., Jensen M. W., Aikman S. L., Harris J. G., Barnes P. J., O'Connor B. J.Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am. J. Respir. Crit. Care Med.156199717311737 |
| 8. | Cockcroft D. W., Swystun V. A., Bhagat R.Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am. J. Respir. Crit. Care Med.152199514851489 |
| 9. | Cockcroft D. W., McParland C. P., Britto S. A., Swystun V. A., Rutherford B. C.Regular inhaled salbutamol and airway responsiveness to allergen. Lancet3421993833837 |
| 10. | Bhagat R., Swystun V. A., Cockcroft D. W.Salbutamol- induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J. Allergy Clin. Immunol.9719964752 |
| 11. | Manolitsas N. D., Wang J., Devalia J. L., Trigg C. J., McAulay A. E., Davies R. J.Regular albuterol, nedocromil sodium, and bronchial inflammation in asthma. Am. J. Respir. Crit. Care Med.151199519251930 |
| 12. | Adelroth E., Rosenhall L., Johansson S. A., Linden M., Venge P.Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage: the effects of antiasthmatic treatment with budesonide or terbutaline. Am. Rev. Respir. Dis.14219909199 |
| 13. | Laitinen L. A., Laitinen A., Haahtela T.A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta-2 agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J. Allergy Clin. Immunol.9019923242 |
| 14. | Adcock I. M., Stevens D. A., Barnes P. J.Interactions of glucocorticoids and beta 2 agonists. Eur. Respir. J.91996160168 |
| 15. | Wong C. S., Wahedna I., Pavord I. D., Tattersfield A. E.Effect of regular terbutaline and budesonide on bronchial reactivity to allergen challenge. Am. J. Respir. Crit. Care Med.150199412681273 |
| 16. | Hancox R. J., Cowan J. O., Flannery E. M., Herbison G. P., McLachlan C. R., Wong C. S., Taylor D. R.A randomized trial of inhaled β–agonist, inhaled corticosteroid and their combination in the treatment of asthma. Thorax541999482487 |
| 17. | Iredale M. J., Wanklyn S. A. R., Phillips I. P., Krausz T., Ind P. W.Non-invasive assessment of bronchial inflammation in asthma: no correlation between eosinophilia of induced sputum and bronchial responsiveness to inhaled hypertonic saline. Clin. Exp. Allergy241994940945 |
| 18. | Yan K., Salome C., Woolcock A. J.Rapid method for measurement of bronchial responsiveness. Thorax381983760765 |
| 19. | Fahy J. V., Liu J., Wong H., Boushey H. A.Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am. Rev. Respir. Dis.147199311261131 |
| 20. | Gauvreau G. M., Jordana M., Watson R. M., Cockroft D. W., O'Byrne P. M.Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am. J. Respir. Crit. Care Med.156199717381745 |
| 21. | Lai C. K., Twentyman O. P., Holgate S. T.The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am. Rev. Respir. Dis.1401989917923 |
| 22. | Nielson C. P., Hadjokas N. E.Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am. J. Respir. Crit. Care Med.571998184191 |
| 23. | Evans D. W., Salome C. M., King G. G., Rimmer S. J., Seale J. P., Woolcock A. J.Effect of regular inhaled salbutamol on airway responsiveness and airway inflammation in rhinitic non-asthmatic subjects. Thorax521997136142 |
| 24. | Smith C. M., Anderson S. D.Inhalation provocation tests using nonisotonic aerosols. J. Allergy Clin. Immunol.841989781790 |
| 25. | Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E.Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am. Rev. Respir. Dis.1421990832836 |
| 26. | Gauvreau G. M., Doctor J., Watson R. M., Jordana M., O'Byrne P. M.Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am. J. Respir. Crit. Care Med.154199612671271 |
| 27. | Claman D. M., Boushey H. A., Liu J., Wong H., Fahy J. V.Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J. Allergy Clin. Immunol.941994861869 |
| 28. | Djukanovic R., Wilson J. W., Britten K. M., Wilson S. J., Walls A. F., Roche W. R., Howarth P. H., Holgate S. T.Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am. Rev. Respir. Dis.1451992669674 |
| 29. | Wilding P. J., Clark M. M., Oborne J., Bennett J. A., Tattersfield A. E.Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax511996989992 |
| 30. | Sears M. R., Taylor D. R., Print C. G., Lake D. C., Flannery E. M., Lucas M. K., Yates D. M., Herbison G. P., Li Q.Regular inhaled β-agonist treatment in bronchial asthma. Lancet336199013911396 |
| 31. | Taylor D. R., Sears M. R., Herbison G. P., Flannery E. M., Print C. G., Lake D. C., Yates D. M., Lucas M. K., Li Q.Regular inhaled β-agonist in asthma: effects on lung function and exacerbations. Thorax481993134138 |
The study was funded by an Otago Research Grant. Dr Aldridge and Dr. Hancox were supported by an educational grant from GlaxoWellcome NZ Ltd. Astra Draco supplied the study medication and matching placebos. Ipratropium bromide was supplied by Boehringer Ingelheim, Germany.
